Transdiagnostic
Joel Wyatt, Ph.D. (he/him/his)
Rush University Medical Center
CHICAGO, IL, Illinois, United States
Andrew Sherrill, Ph.D. (he/him/his)
Assistant Professor
Emory University
Atlanta, Georgia, United States
Joel Wyatt, Ph.D. (he/him/his)
Rush University Medical Center
CHICAGO, IL, Illinois, United States
Mansi Mehta, Ph.D. (she/her/hers)
Postdoctoral fellow
Emory University School of Medicine
Atlanta, Georgia, United States
Stephanie Samph, Ph.D. (she/her/hers)
Clinical Psychologist
MGH/Harvard Medical School
Boston, Massachusetts, United States
Massed treatments utilizing evidenced-based psychotherapies (EBPs) for posttraumatic stress disorder (PTSD) have emerged as a feasible and effective way to treat PTSD in veteran and active duty military populations (Held et al., 2020; Yamokoski et al., 2023). Massed treatments engage participants in treatment between 3 and 10 times per week. Beyond successful post treatment outcomes, patients who engage in massed treatment drop out less. Research shows more than 90%+ of patients complete massed treatment intensive treatment programs, compared to 60% in typical outpatient treatment delivered once-weekly (Kehle-Forbes et al., 2016; Rauch et al., 2020). Moreover, patients have opportunities to improve much faster (e.g., 2-3 weeks vs. 3 months) and tend to maintain these results months after treatment (Held et al., 2020). However, traumatic experiences have been shown to lead to a variety of mental health outcomes and emotional disorders (e.g., Trivedi et al., 2015), such as anxiety and depression, and limiting programs to the treatment of PTSD may exclude patients who would benefit from massed treatment. Patients with trauma histories often present with multiple diagnostic concerns, which is one benefit of utilizing a transdiagnostic approach.
To date, massed treatment delivery has been largely limited to the treatment of PTSD using first line PTSD treatments (i.e., prolonged exposure and cognitive processing therapy). Massed treatment for other concerns, such as anxiety and mood disorders, if is far less understood. This talk reviews the adaption and implementation of the Unified Protocol (UP; Barlow et al., 2011) into three existing intensive treatment programs as an alternative evidence-based psychotherapy offering within historically trauma-focused programs. The Unified Protocol (UP) offers a transdiagnostic approach that fits well into existing programs and allow for patients with a variety of presenting concerns to access evidence-based massed treatment. To date, research examining the effectiveness of massed transdiagnostic treatments, such as the UP, is limited (Sherrill et al. 2024). The present talk will review outcome data from three distinct intensive treatment programs focused on veteran and active duty military populations that have adapted and implemented the UP in a massed format in three different ways. The data to be presented supports the use of a massed delivery model of the UP.
Speaker: Joel D. Wyatt, Ph.D. (he/him/his) – Rush University Medical Center
Co-author: Ashby Boland, B.S. (she/her/hers) – Rush University Medical Center
Co-author: Sarah Pridgen, M.A. – Rush University Medical Center
Co-author: Brian Klassen, PhD – Rush University Medical Center
Co-author: Philip Held, Ph.D. (he/him/his) – Rush University Medical Center
Speaker: Mansi Mehta, Ph.D. (she/her/hers) – Emory University School of Medicine
Co-author: Andrew M. Sherrill, Ph.D. (he/him/his) – Emory University
Co-author: Sheila Rauch, ABPP, Ph.D. (she/her/hers) – Emory University SOM/Atlanta VAMC
Speaker: Stephanie P. Samph, Ph.D. (she/her/hers) – MGH/Harvard Medical School
Co-author: Soyeong Kim, Ph.D. – Massachusetts General Hospital
Co-author: Charlotte Magee, B.A. – Massachusetts General Hospital